A Study to Learn About How a New Pneumococcal Vaccine Works in Adults
NCT ID: NCT07086677
Last Updated: 2025-08-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
372 participants
INTERVENTIONAL
2025-07-22
2027-09-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Participants will receive either:
* an experimental PG4 vaccine
* a PG4 vaccine comparator
* a standard 20vPnC vaccine comparator
* placebo. A placebo does not have any medicine in it but looks just like the study medicine.
Participants will take part in this study for up to 18 months depending on which group they are assigned to. During this time, the participants will receive up to two doses of study vaccine or comparator and take part in follow-up visits.
At these clinic visits, participants will be asked if any side effects were experienced. The participants will also have to give blood samples during clinic visits.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Learn About How a New Pneumococcal Vaccine Works in Infants
NCT06524414
Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults
NCT03828617
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants
NCT00444457
A Phase I Clinical Study to Evaluate the Safety of PCV26 in Individuals ≥60
NCT06970756
A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults
NCT06182124
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PG4 vaccine with low dose adjuvant PA-001; dose schedule 1
PG4 vaccine in Buffer 1 with low dose PA-001
Multivalent pneumococcal conjugate vaccine
PG4 vaccine with low dose adjuvant PA-001; dose schedule 2
PG4 vaccine in Buffer 1 with low dose PA-001
Multivalent pneumococcal conjugate vaccine
PG4 vaccine with low dose adjuvant PA-002; dose schedule 1
PG4 in Buffer 1 with low dose PA-002
Multivalent pneumococcal conjugate vaccine
PG4 vaccine with low dose adjuvant PA-002; dose schedule 2
PG4 in Buffer 1 with low dose PA-002
Multivalent pneumococcal conjugate vaccine
PG4 vaccine with high dose adjuvant PA-001; dose schedule 1
PG4 in Buffer 1 with high dose PA-001
Multivalent pneumococcal conjugate vaccine
PG4 vaccine with high dose adjuvant PA-001; dose schedule 2
PG4 in Buffer 1 with high dose PA-001
Multivalent pneumococcal conjugate vaccine
PG4 vaccine with high dose adjuvant PA-002; dose schedule 1
PG4 vaccine in Buffer 1 with high dose PA-002
Multivalent pneumococcal conjugate vaccine
PG4 vaccine with high dose adjuvant PA-002; dose schedule 2
PG4 vaccine in Buffer 1 with high dose PA-002
Multivalent pneumococcal conjugate vaccine
PG4 vaccine; dose schedule 1
PG4 vaccine in Buffer 2
Multivalent pneumococcal conjugate vaccine
Saline injection
Placebo
PG4 vaccine; dose schedule 2
PG4 vaccine in Buffer 2
Multivalent pneumococcal conjugate vaccine
Saline injection
Placebo
20vPnC; dose schedule 1
20-valent pneumococcal conjugate vaccine
(20vPnC)
Saline injection
Placebo
20vPnC; dose schedule 2
20-valent pneumococcal conjugate vaccine
(20vPnC)
Saline injection
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PG4 vaccine in Buffer 1 with low dose PA-001
Multivalent pneumococcal conjugate vaccine
PG4 in Buffer 1 with low dose PA-002
Multivalent pneumococcal conjugate vaccine
PG4 in Buffer 1 with high dose PA-001
Multivalent pneumococcal conjugate vaccine
PG4 vaccine in Buffer 1 with high dose PA-002
Multivalent pneumococcal conjugate vaccine
PG4 vaccine in Buffer 2
Multivalent pneumococcal conjugate vaccine
20-valent pneumococcal conjugate vaccine
(20vPnC)
Saline injection
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants either with no history of ever receiving a pneumococcal vaccine or who have received a pneumococcal vaccine more than 5 years prior to vaccination in this study
Exclusion Criteria
65 Years
84 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Orange County Research Center
Lake Forest, California, United States
Indago Research & Health Center, Inc
Hialeah, Florida, United States
Johnson County Clinical Trials
Lenexa, Kansas, United States
Velocity Clinical Research, Omaha
Omaha, Nebraska, United States
CTI Clinical Research Center
Cincinnati, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C4931020
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.